ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cyclosporine

Also written as “cyclosporine”, “Cyclosporine A” and “Ciclosporin”.

Its studies are mostly in Dry Eye Syndromes · Dermatitis, Atopic · Bronchiolitis Obliterans Syndrome · Conjunctivitis, Allergic · Bronchiolitis Obliterans, led by 26 companies.

Drug pageCyclosporine: every studyMany companies study it; this page follows only the 81 they lead. All 388 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 6, 200581 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis220 open or runningphase 4since Sep 6, 2005Sep 6, 2005none ahead
Pfizerits history only80 open or runningphase 4since Sep 13, 2005Jun 30, 2004none ahead
Hoffmann-La Rocheits history only70 open or runningphase 4since Jun 30, 2005Jun 30, 2005none ahead
Santen Pharmaceuticalits history only50 open or runningphase 3since May 19, 2006May 19, 2006none ahead
AbbVieits history only40 open or runningphase 4since Apr 22, 2014Apr 17, 2009none ahead
Zambon SpAits history only40 open or runningphase 3since Aug 30, 2018Aug 30, 2018none ahead
Sirion Therapeuticsits history only30 open or runningphase 3since Jul 13, 2007Jul 13, 2007none ahead
Amsterdam Molecular Therapeuticsits history only20 open or runningphase 3since Apr 30, 2009Apr 30, 2009none ahead
APT Pharmaceuticalsits history only20 open or runningphase 3since Sep 17, 2008Sep 17, 2008none ahead
Hanlim Pharm.its history only20 open or runningphase 3since Dec 10, 2012Dec 10, 2012none ahead

Also a collaborator on its studies: Parexel, Dr. Falk Pharma, Syreon and The Clinical Trial.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Sep 6, 2005.

  1. Oct 3, 20052 phase 3 studies in Dermatitis, AtopicNCT00232076, NCT00232063
  2. Nov 30, 2005Phase 4 study in Hepatitis CNCT00260208 · 361 enrolled · United States, Switzerland
  3. May 30, 2006Phase 4 study in Liver TransplantationNCT00332462 · 34 enrolled · Germany
  4. Jan 8, 2007Phase 4 study in Kidney TransplantationNCT00419926 · 313 enrolled · Switzerland
  5. Feb 21, 2007Phase 3 study in Chronic Plaque PsoriasisNCT00438360 · 243 enrolled · Italy
  6. Jul 19, 2007Phase 2 study in Kidney TransplantationNCT00504543 · 311 enrolled · Argentina, Australia, Austria and more
  7. Jul 13, 2009Phase 4 study in Hepatitis CNCT00938860 · 92 enrolled · United States, Belgium, Brazil and more
  8. Jan 12, 2011Phase 3 study in Transplantation InfectionNCT01276457 · 223 enrolled
  9. Sep 29, 2011Phase 2 study in Renal TransplantationNCT01596062 · 16 enrolled · France
  10. Jan 26, 2012Phase 2 study in Dermatitis, AtopicNCT01552629 · 22 enrolled · Austria, France, Germany
  11. Apr 18, 2013Phase 3 study in Rejection, PsychologyNCT01843348 · 612 enrolled · France, Germany
  12. Feb 26, 2015Phase 2 study in Anemia, AplasticNCT02404025 · 10 enrolled · Japan
  13. Nov 4, 2016Phase 2 study in Anemia, AplasticNCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
  14. Mar 9, 2020Phase 2 study in Anemia, AplasticNCT04328727 · 36 enrolled · China, Japan, South Korea and more

TargetBeta

PPIA →read by rule
“Cyclophilin A modulator”ChEMBL 37, by rule

Studies

All 22 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04328727Anemia, Aplastic · China, Japan, South Korea and more2CompletedJun 10, 202236
NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more2CompletedNov 3, 202054
NCT02404025Anemia, Aplastic · Japan2CompletedJul 5, 201610
NCT01843348Rejection, Psychology · France, Germany3CompletedMar 23, 2016612
NCT01552629Dermatitis, Atopic · Austria, France, Germany2CompletedAug 28, 201322
NCT01596062Renal Transplantation · France2CompletedMar 201316
NCT01276457Transplantation Infection3CompletedFeb 2009223
NCT00938860Hepatitis C · United States, Belgium, Brazil and more4CompletedMay 201392
NCT00504543Kidney Transplantation · Argentina, Australia, Austria and more2CompletedApr 2011311
NCT00438360Chronic Plaque Psoriasis · Italy3CompletedNov 2007243
NCT00419926Kidney Transplantation · Switzerland4CompletedJun 2009313
NCT00332462Liver Transplantation · Germany4CompletedApr 200834
NCT00260208Hepatitis C · United States, Switzerland4TerminatedSep 2010361
NCT00232076Dermatitis, Atopic3CompletedMar 2005
NCT00232063Dermatitis, Atopic3CompletedNov 2005
NCT00171743Liver Transplant4CompletedJan 200647
NCT00171509Liver Transplant4CompletedOct 200561
NCT00171496Kidney Transplant4CompletedMar 2006693
NCT00154284Organ Transplantation, Renal Transplantation3CompletedJul 2008114
NCT00154193Heart and Lung Transplant · Switzerland4CompletedNov 2007190
NCT00149994Liver Transplant · Switzerland4CompletedDec 2007171
NCT00149890Infections · Germany3CompletedMar 200977

How it is read

Names in the registry

  • “cyclosporine”, 12 entries
  • “Cyclosporine”, 10 entries
  • “Cyclosporine A”, 6 entries
  • “Ciclosporin”, 4 entries
  • “Liposomal Cyclosporine A”, 3 entries

Codes read as this program: NOVA22007.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.